|
Market Closed -
Nasdaq
16:00:00 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 6.260 USD | +1.29% |
|
-1.57% | +50.48% |
| 08-24 | Precision BioSciences, Inc. Commences Dosing In Phase 1/2 Function-Dmd Study | CI |
| 08-24 | Precision BioSciences Doses First Patient in Trial of Potential Duchenne Muscular Dystrophy Treatment | MT |
| Market Cap | 173M 152M 144M 130M 245M 16.57B 248M 1.72B 664M 8.47B 649M 635M 27.15B | P/E 2026 * |
-1.73x | P/E 2027 * | -2.31x |
|---|---|---|---|---|---|
| Enterprise Value | 173M 152M 144M 130M 245M 16.57B 248M 1.72B 664M 8.47B 649M 635M 27.15B | EV / Sales 2026 * |
12.8x | EV / Sales 2027 * | 19.5x |
| Free-Float |
91.89% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| DTIL | Delayed | |
CBOE
| DTIL | Real-time | |
|
Boerse Muenchen
| PBS0 | Real-time | |
|
Tradegate
| PBS0 | Real-time | |
|
Deutsche Boerse AG
| PBS0 | Delayed | |
|
Börse Stuttgart
| PBS0 | Delayed |
Last Transcript: Precision BioSciences, Inc.
| 1 day | +1.29% | ||
| 1 week | -1.57% | ||
| 1 month | -18.06% | ||
| 3 months | -20.36% | ||
| 6 months | +13.82% | ||
| Current year | +50.48% |
| 1 week | 6 |  | 6.55 |
| 1 month | 6 | | 7.82 |
| Current year | 3.53 | | 9.62 |
| 1 year | 3.53 | | 9.62 |
| 3 years | 3.53 | | 19.43 |
| 5 years | 3.53 | | 348.3 |
| 10 years | 3.53 | | 710.11 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Amoroso
CEO | Chief Executive Officer | 48 | 2021-10-14 |
Jeff Smith
CTO | Chief Tech/Sci/R&D Officer | 53 | 2006-01-25 |
Naresh Tanna
DFI | Director of Finance/CFO | 45 | 2026-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Buehler
CHM | Chairman | 68 | 2020-10-31 |
Geno Germano
BRD | Director/Board Member | 65 | 2020-03-09 |
Stanley Frankel
BRD | Director/Board Member | 67 | 2021-04-11 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/25/26 | Buy | Director | 2,609 | 0.0108% | ||
| 9/25/26 | Buy | Director | 1,135 | 0.0047% | ||
| 8/1/26 | Other | Chief Financial Officer | 251,581 | 1.0451% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.29% | -1.57% | +13.41% | -38.86% | 171M | |
| +4.16% | -0.36% | +49.37% | +94.17% | 71.53B | |
| -0.19% | +1.32% | +37.20% | +83.85% | 60.12B | |
| -1.51% | +2.39% | +9.10% | +35.15% | 48.85B | |
| -0.05% | +0.37% | +41.54% | +36.65% | 44.28B | |
| +0.38% | +7.61% | +339.53% | +641.55% | 43.83B | |
| +0.18% | +0.26% | +7.41% | +103.45% | 41.53B | |
| -0.67% | +0.17% | +7.60% | +46.37% | 30.13B | |
| +4.77% | +6.16% | +36.77% | +22.78% | 27.98B | |
| -1.29% | -3.55% | -20.74% | +352.04% | 25.25B | |
| Average | +0.71% | +0.90% | +52.12% | +137.71% | 39.37B | |
| Weighted average by Cap. | +0.80% | +1.37% | +60.91% | +148.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.48M 11.87M 11.25M 10.16M 19.14M 1.29B 19.39M 135M 51.8M 661M 50.63M 49.53M 2.12B | 8.88M 7.82M 7.4M 6.68M 12.6M 851M 12.76M 88.59M 34.09M 435M 33.33M 32.6M 1.39B |
| Net income | -94.18M -82.94M -78.58M -70.94M -134M -9.03B -135M -940M -362M -4.62B -354M -346M -14.8B | -96.95M -85.37M -80.89M -73.02M -138M -9.3B -139M -968M -372M -4.75B -364M -356M -15.24B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-30 | US$6.260 | +1.29% | 249,244 |
| 26-09-29 | US$6.180 | -0.96% | 154,218 |
| 26-09-28 | US$6.240 | +0.32% | 222,815 |
| 26-09-25 | US$6.220 | -1.74% | 203,993 |
| 26-09-24 | US$6.330 | -0.47% | 401,825 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DTIL Stock
Select your edition
All financial news and data tailored to specific country editions
